Company Overview and News

4
CareDx to Participate in Upcoming Investor Conference

2018-08-15 globenewswire
BRISBANE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in the H. C. Wainwright 20th Annual Global Investment Conference, to be held on September 4-6, 2018 at the St.
CDNA

5
Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?

2018-08-13 zacks
Teladoc Health, Inc. (TDOC - Free Report) stock gained traction from a strong second-quarter 2018 earnings release as well as a solid guidance. The stock hit a 52 week-high of $71.9 on Aug 10.
TDOC CDNA PRAH OPGN

4
CareDx, Inc. (CDNA) CEO Peter Maag on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Greetings, and welcome to the CareDx Second Quarter 2018 Earnings Conference Call. At this time all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
CDNA

4
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks
CareDx (CDNA - Free Report) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
PLNT CDNA GD EPE

4
CDNA / CareDx, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
cdna-10q_20180630.htm
CDNA

4
CDNA / CareDx, Inc. 8-K (Current Report)

2018-08-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CDNA

4
CDNA / CareDx, Inc. FORM 8-K (Current Report)

2018-08-06 sec.gov
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CDNA

2
CDNA / CareDx, Inc. S-8

2018-06-29 sec.gov
S-8 As filed with the Securities and Exchange Commission on June 29, 2018 Registration No. 333-
CDNA

3
CDNA / CareDx, Inc. FORM 8-K (Current Report)

2018-06-28 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CDNA

16
Flatiron Health CMO/CSO Joins CareDx Board of Directors

2018-06-28 globenewswire
BRISBANE, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Amy Abernethy, MD PhD is joining the CareDx Board of Directors.
CDNA ATHN

5
CDNA / CareDx, Inc. FORM 8-K (Current Report)

2018-06-26 sec.gov - 3
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CDNA

2
CDNA / CareDx, Inc. / Alger Associates Inc - SC 13G (Passive Investment)

2018-06-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
CDNA

2
CDNA / CareDx, Inc. / Alger Associates Inc - SC 13G (Passive Investment)

2018-06-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
CDNA

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 14167L103